Navigation Links
Reportlinker Adds The Drug-Eluting Stent Market Outlook to 2016
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Drug-Eluting Stent Market Outlook to 2016

http://www.reportlinker.com/p0483600/The-Drug-Eluting-Stent-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Introduction

The DES market has seen tremendous growth since the introduction of DES in 2003, but the market suffered setbacks in 2007 on the release of clinical data that indicated a link to increased thrombosis. Sales of DES have since stabilized owing to the introduction of novel stents with proven superior therapeutic properties over the traditional bare metal stent.

Features and benefits

* Assess the major market trends including mergers and acquisitions, and licensing agreements and their impact on the market.

* Identify the growth strategies of the leading market players and their likely impact on the future DES market.

* Identify key innovations that will shape the DES market of the future.

* Gain insight into the influence of the emerging economies in determining the present and future DES market size.

* Identify emerging companies that are likely to compete in the near future with the leading DES manufacturers.

Highlights

The DES market has been traditionally characterized by low levels of innovation. However, with the shift in hospital purchasing models from the current sole-supplier model to the capitation pricing model, innovative products are the only ones likely to command premium prices. Thus, this will increase the level of innovation in this segment.

The DES markets in India and China are set to undergo growth in the next five years, concurrent with the improvement of the economies of these two countries and the introduction of the 'Healthy China 2020' plan. However, leading players face stiff competition from local companies in these regions.

Hospitals are currently entering into preferred-supplier agreements whereby they source their medical device requirements from one or two preferred suppliers to leverage volume-based discounts. This puts large suppliers such as Boston Scientific in an advantageous position as they can cater to consolidated spend categories.

Your Key questions answered

* What are the innovations being made in DES technology which of these offers significant potential for future growth?

* What are the key industry trends in terms of mergers and acquisitions and contractual and licensing agreements between buyers and suppliers?

* What are the key regulations in the DES segment and what is the possible impact of new DES technology on the product approval process?

* How have the leading players built a strong position in the DES market and what are their future growth strategies?

* Who are the emerging players in the DES market, what threat do they pose, and what are their business expansion strategies?

TABLE OF CONTENTS

Executive Summary

About Business Insights

Disclaimer

Overview of the global drug-eluting stents market

DES market landscape

Innovations in the DES market

Key players in the DES market

Overview of the global drug-eluting stents market

Summary

Introduction

Position of DES within the cardiac device market

Evolution of DES

Advantage of DES

Market size and forecasts of DES

Historical market size and forecasts

Geographical segmentation

Epidemiology of major cardiovascular diseases

Adoption trends in cardiovascular procedures

Growth drivers

Increased adoption by physicians owing to prevention of late in-stent restenosis

Decreased need for repeat procedures

Demographics – rise in the mean age of the population

Lifestyle changes – increased prevalence of obesity

Growth resistors

High cost of DES compared with BMS

Release of adverse clinical data pertaining to late stent thrombosis

Release of COURAGE data indicating no significant advantage of DES over BMS

Problems associated with Medicare reimbursement of DES

Regulatory changes impacting the DES market

DES market landscape

Summary

Introduction

Market trends

Mergers and acquisitions

Important mergers and acquisitions by leading players

Mergers, acquisitions, and co-exclusivity agreements among emerging players

Preferred supplier agreements

Increased importance of emerging countries

Pricing of DES

Historical prices of DES and trends

Future trends in pricing

Pricing in emerging economies

US Medicare Part A reimbursement costs of DES

Cost-effectiveness of DES versus BMS

Licensing agreements between pharmaceutical companies and DES manufacturers

Innovations in the DES market

Summary

Introduction

Factors driving innovation

Major innovations

Innovations in the polymer component of DES

Drug-coated balloons

Bifurcation stenting

Self-expandable DES

Development of DES with a two-drug offering

Drugs used in DES

New product approvals

FDA approvals

CE mark approvals

Pipeline

Nevo sirolimus-eluting stent (Johnson & Johnson)

Promus and Taxus everolimus-eluting element stents (Boston Scientific)

Taxus Petal paclitaxel-eluting stent (Boston Scientific)

Odyssey (Boston Scientific)

XIENCE Nano (Abbott labs)

Protex coronary stent system (Nexeon MedSystems)

CoroflexDEBlue stent (B. Braun Melsungen)

Key players in the DES market

Summary

Introduction

Relative positioning of the leading market participants

Boston Scientific

Abbott Laboratories

Cordis (Johnson & Johnson)

Medtronic

Product growth and share snapshot

Emerging players

Relative positioning of the emerging market participants

Opto Circuits

Sahajanand Medical Technologies

Blue Medical Devices

Biosensors International

Stentys

MicroPort Scientific

Orbus-Neich Medical

Appendix

Scope

Methodology

Glossary/Abbreviations

References

To order this report:

Drug Delivery Technology Industry: The Drug-Eluting Stent Market Outlook to 2016

Drug Delivery Technology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds The Infusion Pump Market Outlook to 2016
2. Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook
3. Reportlinker Adds Advances in Drug-Diagnostic Co-Development
4. Reportlinker Adds Time and Cost Reduction in Clinical Trials- Outsourcing and IT to Optimize Patient Recruitment, Logistics, Data and Site Management
5. Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
6. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
7. Reportlinker Adds Global: Pharmaceuticals Industry Guide
8. Reportlinker Adds Saxagliptin - Key patent, SPC, and data exclusivity expiry (44 country coverage)
9. Reportlinker Adds Generic Pharmaceuticals Industry - Top 200 Generic Pharmaceuticals Industry (Global)
10. Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
11. Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):